Kupando GmbH Asset Profile

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

Year established

2018

Location

Brandenburg Germany

Primary Industry

Biotechnology

About

Based in Brandenburg, Germany, and founded in 2018, Kupando GmbH is a biopharmaceutical company that develops TLR 4/7 agonists that stimulate innate immunity. In September 2022, the firm raised its series A funding of EUR 13 million, led by investors Remiges Ventures and LifeCare Partners, with participation from other investors such as High-Tech Gründerfonds, Brandenburg Kapital, and Ventura BioMed. The firm as of September 2022 is led by its founder and CEO, Johanna Holldack, and its Chairman, Pierre Morgon. The biopharmaceutical company is working on the development of TLR 4/7 agonists, that targets Toll-Like Receptors (TLRs) responsible for the detection of cancer and infectious molecules, and for the subsequent activation of the innate immune system. The company’s KUP101 is the only TLR 4/7 agonist in development and consists of TLR 4 agonist and a TLR 7 agonist co-encapsulated in a liposomal formulation this compound induces a broad immune response, which will facilitate its development as an anti-tumor agent in combination with other anti-tumor modalities, or a prophylactic vaccine for infectious diseases. This provides a multitude of options for administration routes and applications in Oncology and other infectious diseases. The company plans to utilize its September 2022 funding to complete the IND preparatory work and start the clinical development of its lead candidate KUP101 in a solid tumor indication.

Current Investors

High-Tech Grunderfonds, Brandenburg Kapital, Remiges Ventures

Request a demo to show more

Primary Industry

Biotechnology

Sub Industries

Biopharmaceuticals

Website

www.kupando.com

Company Stage

Series A

Total Amount Raised

Subscriber access only

Employee Data

Want to see the Employee Count?

Request a demo for full access to this profile.

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.